Market News / Story
Valion Bio names Thomas Jensen as board chair, highlights $35.6M non-dilutive support and FDA designations for Entolimod
·
Valion Bio announced Thomas Jensen as new Board Chair and emphasized Entolimod's $35.6 million in government funding plus Fast Track and Orphan Drug designations. Key Highlights: Thomas H. Jensen appointed Board Chair and will work with management to align strategic priorities and execution. Entolimod program has received approximately $35.6 million in non-dilutive U.S. government funding, supporting continued development. Entolimod holds FDA Fast Track and Orphan Drug…